Anglo-Swiss pharmaceutical company AstraZeneca PLC reported that first-quarter profit rose by 29 percent, but cautioned that comparisons will be tougher in the second half of the year when a key patent expires.
endpoint Clinical announced that PULSE, a fully configurable platform that allows users to design and deploy clinical trial Integrated Response Technology (IRT) systems, saves 40 percent on the development time of clinical trials.
Citeline’s TrialTrove, a leading global pharmaceutical intelligence service, now tracks more than 100,000 clinical trials around the world, making it among the most comprehensive source of clinical trial information available.
ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, announced the launch of Centralized Cardiac Safety 2.0, a portfolio of new solutions that enable a significant new approach to cardiac safety in clinical trials.
Almac Clinical Technologies announced the release of a new reporting solution for its IXRS integrated phone and web response technology, Almac Interactive Reporting.
Fluidigm Corporation released a protocol for the Access Array System that enables sequencing of amplicon libraries using GS FLX Titanium Series reagents on the 454 GS FLX sequencing system.
Life Technologies Corporation debuted the life science industry’s first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols.
Debiopharm Group announced that it has started patient enrolment in its Phase 1 clinical trial for the small molecule inhibitor of heat shock protein 90 (Hsp90), Debio 0932.
Shire plc announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. advising of the filing of an abbreviated new drug application for a generic version of Shire’s INTUNIV.
Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.
Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions.
Phase Forward Inc., a provider of data management software for drug safety and clinical trials, said its first-quarter profit fell 53 percent as business costs and operating expenses outstripped modest revenue gains.
The overall increase in profit came as revenues at the company, which also makes the cancer drug Erbitux and multiple sclerosis treatment Rebif, rose nearly 13 percent to nearly €2.1 billion in the January-March period compared with nearly €1.9 billion a year earlier.
With a few drops of blood, scientists are creating a way to tell who's absorbed dangerous radiation levels, part of the government's preparations against a terrorist attack - and research that just might point toward new cancer care, too.